These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

823 related items for PubMed ID: 28314836

  • 1. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM.
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [Abstract] [Full Text] [Related]

  • 2. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM.
    Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
    [Abstract] [Full Text] [Related]

  • 3. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [Abstract] [Full Text] [Related]

  • 4. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [Abstract] [Full Text] [Related]

  • 5. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS.
    J Am Coll Cardiol; 2011 May 31; 57(22):2263-70. PubMed ID: 21616287
    [Abstract] [Full Text] [Related]

  • 6. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart MJ, de Azambuja E.
    J Clin Oncol; 2017 Mar 10; 35(8):878-884. PubMed ID: 28199174
    [Abstract] [Full Text] [Related]

  • 7. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA.
    Cancer J; 2015 Mar 10; 21(5):357-64. PubMed ID: 26389758
    [Abstract] [Full Text] [Related]

  • 8. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.
    JAMA Oncol; 2016 Jan 10; 2(1):29-36. PubMed ID: 26539793
    [Abstract] [Full Text] [Related]

  • 9. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Xu N, Smitt M, Gianni L.
    J Clin Oncol; 2015 Apr 01; 33(10):1136-42. PubMed ID: 25713436
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH.
    JAMA Oncol; 2016 Aug 01; 2(8):1030-7. PubMed ID: 27348762
    [Abstract] [Full Text] [Related]

  • 11. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
    Cao L, Cai G, Chang C, Miao AY, Yu XL, Yang ZZ, Ma JL, Zhang Q, Wu J, Guo XM, Chen JY.
    Oncologist; 2015 Jun 01; 20(6):605-14. PubMed ID: 25933931
    [Abstract] [Full Text] [Related]

  • 12. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M, Munster P, Fink A, Krischer J.
    Am Heart J; 2017 Jun 01; 188():87-92. PubMed ID: 28577685
    [Abstract] [Full Text] [Related]

  • 13. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C, Torelli F, Ghiselli L, Rossi A, Trevisani L, Vinco G, Truong S, Benfari G, LA Russa F, Golia G, Molino A, Vassanelli C.
    Minerva Cardioangiol; 2017 Jun 01; 65(3):278-287. PubMed ID: 27886160
    [Abstract] [Full Text] [Related]

  • 14. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
    Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Aalders K, Bartlett JMS, Biganzoli L, Bogaerts J, Cameron D, EORTC- Breast Cancer Group.
    Breast Cancer Res Treat; 2017 Jun 01; 163(3):507-515. PubMed ID: 28324265
    [Abstract] [Full Text] [Related]

  • 15. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F.
    BMC Cancer; 2017 Jun 19; 17(1):425. PubMed ID: 28629338
    [Abstract] [Full Text] [Related]

  • 16. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC, de Boer M, Derksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, Joore M, Peer PG, Voogd AC, Tjan-Heijnen VC.
    Oncologist; 2016 May 19; 21(5):555-62. PubMed ID: 27009939
    [Abstract] [Full Text] [Related]

  • 17. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA.
    Breast Cancer Res Treat; 2012 Jul 19; 134(1):291-8. PubMed ID: 22476854
    [Abstract] [Full Text] [Related]

  • 18. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI.
    J Clin Oncol; 2017 Mar 10; 35(8):870-877. PubMed ID: 27893331
    [Abstract] [Full Text] [Related]

  • 19. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, Haq R, Kirpalani A, Chan KKW, Petrella TM, Brezden-Masley C.
    Int J Cardiovasc Imaging; 2019 Nov 10; 35(11):2085-2093. PubMed ID: 31197526
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA, Aksoy S, Yorgun H, Ozdemir N, Yilmaz FM, Yazıcı O, Zungun C, Aytemir K, Zengin N, Altundag K.
    Curr Med Res Opin; 2015 Mar 10; 31(3):547-56. PubMed ID: 25586297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.